PAUL HEFFINGTON: Open Payments
NPI 1093087850 · AIKEN, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,490 in 60 payments from 12 companies in 2025. Trend: 2023 $860 · 2024 $1,057 · 2025 $1,490
Food & beverage: $1,490
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 19 | $312 |
| Otsuka America Pharmaceutical, Inc. | 9 | $286 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $234 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $207 |
| E.R. Squibb & Sons, L.L.C. | 2 | $144 |
| ABBVIE INC. | 5 | $142 |
| Neurocrine BioSciences, Inc. | 2 | $47 |
| Lundbeck LLC | 2 | $38 |
| Axsome Therapeutics, Inc. | 1 | $24 |
| Alkermes, Inc. | 1 | $19 |
Products named: REXULTI, TRINTELLIX, CAPLYTA, UZEDY, AUSTEDO XR, COBENFY, VRAYLAR, INGREZZA.
Industry payments across SC — which companies pay providers there.
